Nxstage Medical (NXTM) Tops Q1 EPS by 3c; Sees FY16 Results at High-End of Expectations

Nxstage Medical (NASDAQ: NXTM) reported Q1 EPS of ($0.02), $0.03 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $89.2 million versus the consensus estimate of $88.4 million.

GUIDANCE:

Nxstage Medical sees Q2 2016 revenue of $89-91 million, versus the consensus of $87.4 million.

The Company now expects full-year revenue for 2016 to be at the high end of its previous guidance range of $355 to $360 million with unchanged guidance for a net loss in the range of $7 to $12 million.

For earnings history and earnings-related data on Nxstage Medical (NXTM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49